MTR
Basic information
Region (hg38): 1:236795260-236921278
Links
Phenotypes
GenCC
Source:
- methylcobalamin deficiency type cblG (Definitive), mode of inheritance: AR
- methylcobalamin deficiency type cblG (Supportive), mode of inheritance: AR
- methylcobalamin deficiency type cblG (Strong), mode of inheritance: AR
- methylcobalamin deficiency type cblG (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Homocystinuria-megaloblastic anemia, cblG complementation type | AR | Biochemical | Medical treatment may be beneficial (while hydroxycobalamin may not be as effective as in other MMA types, other treatments, such as betaine, methylfolate, and even methionine supplements may be attempted) | Biochemical; Cardiovascular; Hematologic; Neurologic; Renal | 2897628; 2203337; 8968736; 8968737; 12068375; 20301503; 22108709 |
ClinVar
This is a list of variants' phenotypes submitted to
- Methylcobalamin deficiency type cblG (46 variants)
- not provided (6 variants)
- Disorders of Intracellular Cobalamin Metabolism (1 variants)
- Epilepsy;Intellectual disability, profound (1 variants)
- MTR-related disorder (1 variants)
- Decreased methionine synthase activity;Homocystinuria (1 variants)
- Inborn genetic diseases (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the MTR gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 287 | 299 | ||||
missense | 214 | 234 | ||||
nonsense | 14 | 15 | ||||
start loss | 1 | |||||
frameshift | 27 | 31 | ||||
inframe indel | 1 | |||||
splice donor/acceptor (+/-2bp) | 20 | 27 | ||||
splice region | 1 | 20 | 70 | 8 | 99 | |
non coding | 116 | 276 | 147 | 542 | ||
Total | 48 | 32 | 337 | 573 | 160 |
Highest pathogenic variant AF is 0.0000854
Variants in MTR
This is a list of pathogenic ClinVar variants found in the MTR region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
1-236795291-C-A | Disorders of Intracellular Cobalamin Metabolism | Uncertain significance (Jan 13, 2018) | ||
1-236795325-C-T | Disorders of Intracellular Cobalamin Metabolism | Uncertain significance (Jan 13, 2018) | ||
1-236795348-C-G | Disorders of Intracellular Cobalamin Metabolism | Uncertain significance (Jan 12, 2018) | ||
1-236795360-C-T | Disorders of Intracellular Cobalamin Metabolism | Uncertain significance (Apr 27, 2017) | ||
1-236795376-T-G | Disorders of Intracellular Cobalamin Metabolism | Uncertain significance (Jan 12, 2018) | ||
1-236795383-C-G | Disorders of Intracellular Cobalamin Metabolism | Likely benign (May 19, 2021) | ||
1-236795395-G-A | Disorders of Intracellular Cobalamin Metabolism | Uncertain significance (Jan 12, 2018) | ||
1-236795455-C-T | Disorders of Intracellular Cobalamin Metabolism | Uncertain significance (Jan 13, 2018) | ||
1-236795503-C-G | Disorders of Intracellular Cobalamin Metabolism | Benign/Likely benign (Jun 29, 2018) | ||
1-236795506-C-G | Disorders of Intracellular Cobalamin Metabolism | Uncertain significance (Jan 13, 2018) | ||
1-236795531-G-A | Disorders of Intracellular Cobalamin Metabolism | Uncertain significance (Jan 12, 2018) | ||
1-236795531-G-T | Disorders of Intracellular Cobalamin Metabolism | Likely benign (Jan 12, 2018) | ||
1-236795553-C-T | Disorders of Intracellular Cobalamin Metabolism | Benign/Likely benign (Feb 01, 2023) | ||
1-236795571-G-A | Disorders of Intracellular Cobalamin Metabolism | Uncertain significance (Jun 14, 2016) | ||
1-236795593-C-T | Disorders of Intracellular Cobalamin Metabolism | Benign/Likely benign (May 13, 2021) | ||
1-236795596-G-C | Disorders of Intracellular Cobalamin Metabolism | Uncertain significance (Jan 13, 2018) | ||
1-236795608-C-A | Disorders of Intracellular Cobalamin Metabolism | Uncertain significance (Jan 13, 2018) | ||
1-236795637-C-T | Disorders of Intracellular Cobalamin Metabolism | Benign (Nov 03, 2019) | ||
1-236795685-AAGG-A | not specified | Likely benign (Feb 11, 2016) | ||
1-236795698-G-C | Disorders of Intracellular Cobalamin Metabolism | Uncertain significance (Dec 16, 2022) | ||
1-236795703-CAT-C | Likely pathogenic (Oct 11, 2017) | |||
1-236795709-A-G | Methylcobalamin deficiency type cblG | Likely benign (Dec 13, 2022) | ||
1-236795711-CCG-C | Methylcobalamin deficiency type cblG | Pathogenic (Dec 04, 2023) | ||
1-236795712-C-T | Methylcobalamin deficiency type cblG | Likely benign (Jul 19, 2023) | ||
1-236795716-C-A | Methylcobalamin deficiency type cblG • Inborn genetic diseases | Uncertain significance (Dec 06, 2022) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
MTR | protein_coding | protein_coding | ENST00000366577 | 33 | 108672 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
2.43e-12 | 1.00 | 125655 | 0 | 93 | 125748 | 0.000370 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 2.04 | 527 | 677 | 0.779 | 0.0000371 | 8317 |
Missense in Polyphen | 171 | 297.93 | 0.57395 | 3623 | ||
Synonymous | -0.582 | 259 | 247 | 1.05 | 0.0000145 | 2384 |
Loss of Function | 4.05 | 31 | 66.7 | 0.465 | 0.00000350 | 852 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000536 | 0.000535 |
Ashkenazi Jewish | 0.000611 | 0.000595 |
East Asian | 0.000544 | 0.000544 |
Finnish | 0.000188 | 0.000185 |
European (Non-Finnish) | 0.000380 | 0.000378 |
Middle Eastern | 0.000544 | 0.000544 |
South Asian | 0.000409 | 0.000392 |
Other | 0.000654 | 0.000652 |
dbNSFP
Source:
- Function
- FUNCTION: Catalyzes the transfer of a methyl group from methyl- cobalamin to homocysteine, yielding enzyme-bound cob(I)alamin and methionine. Subsequently, remethylates the cofactor using methyltetrahydrofolate (By similarity). {ECO:0000250}.;
- Disease
- DISEASE: Homocystinuria-megaloblastic anemia, cblG complementation type (HMAG) [MIM:250940]: An autosomal recessive inborn error of metabolism resulting from defects in the cobalamin-dependent pathway that converts homocysteine to methionine. It causes delayed psychomotor development, megaloblastic anemia, homocystinuria, and hypomethioninemia. {ECO:0000269|PubMed:8968736, ECO:0000269|PubMed:8968737}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Neural tube defects, folate-sensitive (NTDFS) [MIM:601634]: The most common NTDs are open spina bifida (myelomeningocele) and anencephaly. {ECO:0000269|PubMed:12375236}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.;
- Pathway
- Antimetabolite Pathway - Folate Cycle, Pharmacodynamics;One carbon pool by folate - Homo sapiens (human);Cysteine and methionine metabolism - Homo sapiens (human);Selenocompound metabolism - Homo sapiens (human);Methotrexate Pathway (Cancer Cell), Pharmacodynamics;Thiopurine Pathway, Pharmacokinetics/Pharmacodynamics;S-Adenosylhomocysteine (SAH) Hydrolase Deficiency;Methionine Metabolism;Methionine Adenosyltransferase Deficiency;Glycine N-methyltransferase Deficiency;Hypermethioninemia;Methylenetetrahydrofolate Reductase Deficiency (MTHFRD);Betaine Metabolism;Homocystinuria-megaloblastic anemia due to defect in cobalamin metabolism, cblG complementation type;sarcosine oncometabolite pathway ;Cystathionine Beta-Synthase Deficiency;Selenium Micronutrient Network;Vitamin B12 Metabolism;Folate-Alcohol and Cancer Pathway Hypotheses;Folate Metabolism;Trans-sulfuration pathway;One Carbon Metabolism;Trans-sulfuration and one carbon metabolism;Methionine De Novo and Salvage Pathway;One carbon metabolism and related pathways;Ethanol effects on histone modifications;Methylation;Phase II - Conjugation of compounds;Folate metabolism;Metabolism of amino acids and derivatives;Biological oxidations;Cobalamin (Cbl, vitamin B12) transport and metabolism;Metabolism;folate transformations I;Methionine Cysteine metabolism;methionine salvage;Metabolism of water-soluble vitamins and cofactors;Metabolism of vitamins and cofactors;Sulfur amino acid metabolism
(Consensus)
Recessive Scores
- pRec
- 0.687
Intolerance Scores
- loftool
- 0.507
- rvis_EVS
- 0.25
- rvis_percentile_EVS
- 69.7
Haploinsufficiency Scores
- pHI
- 0.691
- hipred
- Y
- hipred_score
- 0.736
- ghis
- 0.529
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.965
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | High |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Mtr
- Phenotype
- homeostasis/metabolism phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span);
Gene ontology
- Biological process
- nervous system development;methionine biosynthetic process;cobalamin metabolic process;axon regeneration;methylation;pteridine-containing compound metabolic process;response to axon injury;cellular response to nitric oxide
- Cellular component
- cytosol
- Molecular function
- protein binding;zinc ion binding;methionine synthase activity;cobalamin binding